TC-G 1004

Pricing Availability   Qty
Description: Potent and selective A2A antagonist
Chemical Name: N-[2-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-[6-(4-methoxy-1-piperidinyl)-2-pyridinyl]-4-pyrimidinyl]acetamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (1)

Biological Activity for TC-G 1004

TC-G 1004 is a potent antagonist of adenosine A2A receptors; displays >100-fold selectivity for A2A over A1 receptors (Ki values are 0.44 and 85 nM respectively). Potentiates L-DOPA-induced rotational behavior in 6-OHDA-lesioned rats.

Technical Data for TC-G 1004

M. Wt 421.5
Formula C22H27N7O2
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1061747-72-5
PubChem ID 25074316
InChI Key JENSDTKXNVHSSN-UHFFFAOYSA-N
Smiles CC1=CC(C)=NN1C2=NC(C3=CC=CC(N4CCC(OC)CC4)=N3)=CC(NC(C)=O)=N2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for TC-G 1004

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
1eq. HCl 42.15 100
DMSO 42.15 100

Preparing Stock Solutions for TC-G 1004

The following data is based on the product molecular weight 421.5. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.37 mL 11.86 mL 23.72 mL
5 mM 0.47 mL 2.37 mL 4.74 mL
10 mM 0.24 mL 1.19 mL 2.37 mL
50 mM 0.05 mL 0.24 mL 0.47 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for TC-G 1004

References are publications that support the biological activity of the product.

Zhang et al (2008) Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease. J.Med.Chem. 51 7099 PMID: 18947224


If you know of a relevant reference for TC-G 1004, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Adenosine A2A Receptor Antagonists

Keywords: TC-G 1004, TC-G 1004 supplier, TC-G1004, adenosine, A2A, receptors, selective, potent, antagonists, Adenosine, Receptors, 4407, Tocris Bioscience

Citations for TC-G 1004

Citations are publications that use Tocris products.

Currently there are no citations for TC-G 1004. Do you know of a great paper that uses TC-G 1004 from Tocris? Please let us know.

Reviews for TC-G 1004

There are currently no reviews for this product. Be the first to review TC-G 1004 and earn rewards!

Have you used TC-G 1004?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.